Author Archives: Steve Bryson PhD

Low daily doses of Esbriet (pirfenidone), less than 1200 mg per day, are equally effective at slowing lung function decline in people with idiopathic pulmonary fibrosis (IPF) as higher daily doses, a real-world analysis found.  Lower doses may help to limit therapy…

No significant differences in survival rates, extending out 10 years, were found in idiopathic pulmonary fibrosis (IPF) patients given either a single- or double-lung transplant, a study reports. These findings, based on data cover more than 2,000 IPF patients who underwent either, suggest a bias in studies favoring a…

Simultaneous inhibition of two signaling pathways mediated by TGF-beta1 and periostin can halt progression of idiopathic pulmonary fibrosis in mice, a new study reveals.  The study, “The Cross-Talk Between TGF-β and Periostin Can Be Targeted for Pulmonary Fibrosis,” was published in…

Genetic screening that can identify variants of the mucin-causing MUC5B gene — the key risk factor that predisposes people for idiopathic pulmonary fibrosis (IPF) — may hold the key to the development and administration of targeted therapies that may prevent the disease before it can progress…

Efforts to optimize treatments to address critical challenges in treating idiopathic pulmonary fibrosis (IPF) has been given a boost by a more than CA$670,000 grant to support a collaborative project between Ceapro and academic researchers at McMaster…

Inflammatory bowel disease (IBD) increases the risk of developing idiopathic pulmonary fibrosis (IPF), particularly in male patients with Crohn’s disease, a large-scale population study shows.  The study, “Increased Risk of Idiopathic Pulmonary Fibrosis…

The natural product tannic acid has anti-fibrotic effects on cultured human lung fibroblasts and in an in vivo idiopathic pulmonary fibrosis (IPF) mouse model by reducing signals from TGF-beta receptors, a new study has found. The study, “…

The Pulmonary Fibrosis Foundation (PFF) announced that its nationwide Care Center Network (CCN) now encompasses 68 medical centers in 33 states, following the addition of eight sites with recognized expertise in pulmonary fibrosis (PF) diagnosis, treatment,…